FIG 1.

Plasma neutralization titers of nasopharyngeal carcinoma cases and control groups. (A) Neutralizing ability against Epstein-Barr virus (EBV) infection of epithelial cells represented by 50% inhibitory dilution (ID₅₀) in nasopharyngeal carcinoma (NPC) cases, high-risk healthy controls (HC), and low-risk healthy controls (LC). (B) Neutralizing ability (ID₅₀) against EBV infection of B cells in NPC cases, HC, and LC. (C) Correlation between the neutralizing ability (ID₅₀) against EBV infection of B cells and that of epithelial cells. For definitions of significance symbols for all figures, see Materials and Methods.